Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus HI COR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus HI COR.
ASMANEX HFA vs HI-COR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin and leukotriene synthesis.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
0.1-0.2 mg/kg intravenously once.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
Terminal elimination half-life is 2-4 hours. Clinical context: Short half-life requires frequent dosing for sustained effect; accumulation possible in renal impairment.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Renal excretion of unchanged drug and metabolites accounts for approximately 70-80% of elimination, with biliary/fecal excretion contributing 20-30%.
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid